NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Sen YanHan ZengKaifeng JinFei ShaoZhaopei LiuYuan ChangYiwei WangYu ZhuZewei WangLe XuJiejie XuPublished in: Journal for immunotherapy of cancer (2022)
NKG2A and PD-L1 expression panel was associated with an immune inflamed microenvironment and acted as a combinatorial biomarker to predict the therapeutic response to ACT and PD-L1 blockade in MIBC.